Adrx, Inc.
Thousand Oaks, CA
- UEI
- JQ76MYFLKYB4
- CAGE
- 6XZ21
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 515 Marin St #314, Thousand Oaks, CA 91360, USA
- Website
- adrxpharma.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Oligomerix Inc. | NY | — |
| Bolden Therapeutics Inc. | Providence, RI | — |
| Amydis, Inc. | San Diego, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Virogenics, Inc. | San Diego, CA | 238990 All Other Specialty Trade Contractors |
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Adrx, Inc. Division - doing business as Adrx Inc. is a corporate entity registered to receive federal grants and contracts. Its work through federal grant awards appears to be focused on research and development of therapeutics and diagnostics, particularly for neurodegenerative diseases like Alzheimer's disease and rare conditions like transthyretin amyloidosis.
In recent years, Adrx has received several significant project grants from the National Institutes of Health (NIH) and its institutes like the National Institute on Aging, National Center for Advancing Translational Sciences, and National Institute of General Medical Sciences. A $953,102 grant is supporting Adrx's work on developing brain-penetrant small molecules to directly target and disaggregate tau protein aggregates associated with Alzheimer's disease pathology. Adrx is leveraging structure-based drug design and medicinal chemistry optimization approaches through this Aging Research program award. Another $540,552 grant from the National Center for Advancing Translational Sciences is enabling Adrx to generate proof-of-concept data for a rapid, non-invasive blood diagnostic to detect monomeric transthyretin protein, an early biomarker of transthyretin amyloidosis. Additionally, a $512,166 grant from the National Institute of General Medical Sciences is funding research on using Adrx's proprietary antibodies to deplete aberrant, aggregation-prone transthyretin monomers from the blood as a potential therapeutic approach for transthyretin amyloidosis.
Quick answers
Is Adrx, Inc. registered in SAM.gov?
Yes. Adrx, Inc.'s SAM.gov registration is active through December 22, 2026.
What is Adrx, Inc.'s most recent federal award?
Adrx, Inc.'s most recent federal grant award is Brain-penetrant chemical disaggregators of TAU fibrils as therapeutics for alzheimer's disease (R43AG073018), from National Institute on Aging (NIH), on September 1, 2022.
On GovTribe
See Adrx, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors